At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Closed 12-09 16:00:00 EST
10.72
+2.36
+28.23%
盘后10.73
+0.01+0.09%
19:59 EST
High12.82Low8.95Vol41.90M
Open10.56D1 Closing8.36Amplitude46.32%
Mkt Cap234.88MTradable Cap203.37MTotal Shares21.91M
T/O473.85MT/O Rate220.83%Tradable Shares18.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-ATMC, G-III Apparel, Cognyte
Reuters  ·  12-09 22:35
BUZZ-U.S. STOCKS ON THE MOVE-ATMC, G-III Apparel, Cognyte
Vor Biopharma Shares up 13% After JP Morgan Initiates Coverage With 'Overweight'
THOMSON REUTERS  ·  12-09 22:33
Vor Biopharma Shares up 13% After JP Morgan Initiates Coverage With 'Overweight'
Vor Biopharma Cuts Stock Option Exercise Price to $8.18 for Executives
Reuters  ·  12-09 20:59
Vor Biopharma Cuts Stock Option Exercise Price to $8.18 for Executives
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Ares Management, Vor Bio
Reuters  ·  12-09 20:39
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Ares Management, Vor Bio
Top Premarket Gainers
MT Newswires Live  ·  12-09 20:37
Top Premarket Gainers
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating
Reuters  ·  12-09 19:49
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating
Vor Biopharma Shares Jump 67% Premarket After JP Morgan Initiates Coverage With 'Overweight'
THOMSON REUTERS  ·  12-09 19:45
Vor Biopharma Shares Jump 67% Premarket After JP Morgan Initiates Coverage With 'Overweight'
Vor Biopharma Coverage Assumed by Wedbush at Neutral
Dow Jones  ·  11-25
Vor Biopharma Coverage Assumed by Wedbush at Neutral
Vor Biopharma (VOR) Gets a Hold from Wedbush
TIPRANKS  ·  11-25
Vor Biopharma (VOR) Gets a Hold from Wedbush
Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating
MT Newswires Live  ·  11-25
Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating
Vor Biopharma Reports Q3 2025 Financial Results and Strategic Updates
TIPRANKS  ·  11-18
Vor Biopharma Reports Q3 2025 Financial Results and Strategic Updates
Vor Bio price target lowered to $32 from $55 at H.C. Wainwright
TIPRANKS  ·  11-14
Vor Bio price target lowered to $32 from $55 at H.C. Wainwright
UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate
Benzinga  ·  11-14
UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate
Vor Biopharma Q3 EPS $(121.63) May Not Compare To $(3.32) Estimate
Benzinga  ·  11-14
Vor Biopharma Q3 EPS $(121.63) May Not Compare To $(3.32) Estimate
Vor Biopharma reports third quarter loss and reduced R&D expenses
Reuters  ·  11-14
Vor Biopharma reports third quarter loss and reduced R&D expenses
Vor Biopharma Announces $93.7 Million Public Offering
TIPRANKS  ·  11-12
Vor Biopharma Announces $93.7 Million Public Offering
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
Benzinga  ·  11-12
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
Vor Biopharma Shares Fall 46.9% After Steeply Discounted $100 Mln Stock Offering
THOMSON REUTERS  ·  11-11
Vor Biopharma Shares Fall 46.9% After Steeply Discounted $100 Mln Stock Offering
BUZZ-U.S. STOCKS ON THE MOVE-Nebius, Estee Lauder, Soleno
Reuters  ·  11-11
BUZZ-U.S. STOCKS ON THE MOVE-Nebius, Estee Lauder, Soleno
Top Premarket Decliners
MT Newswires Live  ·  11-11
Top Premarket Decliners

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--